China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving approval from the National Medical Products Administration (NMPA) to initiate clinical studies for its Category 1 chemical drug HSK44459. The drug will be assessed for use in treating psoriasis and atopic dermatitis (AD), chronic, recurrent, and immune-inflammatory skin diseases with significant unmet clinical needs.
Drug Profile and Mechanism
HSK44459 is a phosphodiesterase 4B (PDE4B) inhibitor. Pre-clinical studies have demonstrated its clear targets, precise efficacy, and good safety profile. This approval marks a significant step forward in the development of HSK44459, which previously received clinical approval in China for interstitial lung disease and Behcet’s disease.
Clinical Trial Significance
The initiation of these clinical studies represents a crucial milestone for Haisco Pharmaceutical. The trials will evaluate the safety and efficacy of HSK44459 in patients with psoriasis and atopic dermatitis, potentially offering new treatment options for these chronic conditions.-Fineline Info & Tech
Leave a Reply